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Recent evidence on the chemoprevention of breast can-
cer has come from a number of sources:
1) Recent data on two new SERMs – lasofoxifene and
arzoxifene– suggests they might be an attractive option,
but further details are needed to fully evaluate their role.
2) Update on the tamoxifen and raloxifene preventive
trials have shown a continued benefit after treatment
completion, and an overview is ongoing to combine all
the post-treatment data on risks and benefits. Latest
results from the STAR trial indicate that raloxifene is
less efficacious than tamoxifen but has fewer side effects.
A full new overview is in progress.
3) A report from the ATAC trial indicating that the
occurrence of endocrine symptoms predicts response to
both tamoxifen and anastrozole may also have relevance
in the preventive setting.
4) Long term follow-up of the adjuvant trials using
aromatase trials has provided new evidence on the dura-
tion of a potential preventive effect by looking at iso-
lated new contralateral tumours. This has been an
excellent model for tamoxifen and may well also be so
for the AIs.
5) A very recent report from the MAP3 (Goss,
NEJM,2011) indicates that after 35 months median fol-
low up , a 60% reduction in new tumours was seen ,
confirming predictions made from contralateral tumours
in adjuvant trials.
6) New data confirm the long term protective effect of
aspirin on breast cancer, but suggests it needs to be
taken for at least 5 years to get a benefit. Mixed data
have appeared for the statins.
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